These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 20507361)

  • 41. Connective tissue disease: SSc-fibrosis takes flight with Wingless inhibition.
    Lafyatis R
    Nat Rev Rheumatol; 2012 Aug; 8(8):441-2. PubMed ID: 22751566
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Scleroderma].
    Hasegawa M; Takehara K; Sato S
    Nihon Rinsho; 2005 May; 63 Suppl 5():295-9. PubMed ID: 15954365
    [No Abstract]   [Full Text] [Related]  

  • 43. Animal models of systemic sclerosis: insights into systemic sclerosis pathogenesis and potential therapeutic approaches.
    Christner PJ; Jimenez SA
    Curr Opin Rheumatol; 2004 Nov; 16(6):746-52. PubMed ID: 15577614
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Scleroderma: Pathogenesis, pathophysiology, and therapy].
    Imai H; Suzuki K
    Nihon Rinsho; 2006 Feb; 64 Suppl 2():446-9. PubMed ID: 16523931
    [No Abstract]   [Full Text] [Related]  

  • 45. Antifibrotic therapy in scleroderma: extracellular or intracellular targeting of activated fibroblasts?
    Varga J
    Curr Rheumatol Rep; 2004 Apr; 6(2):164-70. PubMed ID: 15016348
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Scleroderma renal crisis.
    Hudson M
    Curr Opin Rheumatol; 2015 Nov; 27(6):549-54. PubMed ID: 26352732
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Current frontiers in systemic sclerosis pathogenesis.
    Ciechomska M; van Laar J; O'Reilly S
    Exp Dermatol; 2015 Jun; 24(6):401-6. PubMed ID: 25712746
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Scleroderma: the need for extreme remedies.
    Olsen NJ
    Am J Med Sci; 2011 Nov; 342(5):416-21. PubMed ID: 21233696
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The pathogenesis of fibrosis and renal disease in scleroderma: recent insights from glomerulosclerosis.
    Lee S; Lee S; Sharma K
    Curr Rheumatol Rep; 2004 Apr; 6(2):141-8. PubMed ID: 15016345
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Vascular abnormalities in scleroderma.
    Herron GS; Romero LI
    Semin Cutan Med Surg; 1998 Mar; 17(1):12-7. PubMed ID: 9512101
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Progressive systemic sclerosis: Part 1--The disease and medical management.
    Larrabee JH
    ANNA J; 1989 Dec; 16(7):489-93. PubMed ID: 2690757
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A radical proposal for the pathogenesis of scleroderma.
    Murrell DF
    J Am Acad Dermatol; 1993 Jan; 28(1):78-85. PubMed ID: 8425975
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Scleroderma: pathogenic factors and current management.
    Penny R
    Aust N Z J Med; 1978; 8 Suppl 1():143-8. PubMed ID: 365159
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Sixth international workshop on scleroderma research, Oxford, UK, 30 July--22 August 2000.
    Wollheim FA; Denton CP; Abraham DJ
    Arthritis Res; 2001; 3(1):34-40. PubMed ID: 11269238
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A unifying hypothesis for scleroderma: identifying a target cell for scleroderma.
    Mahoney WM; Fleming JN; Schwartz SM
    Curr Rheumatol Rep; 2011 Feb; 13(1):28-36. PubMed ID: 21181314
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Connective tissue metabolism in scleroderma, including cytokines.
    Unemori EN; Amento EP
    Curr Opin Rheumatol; 1996 Nov; 8(6):580-4. PubMed ID: 9018463
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Vascular disease in scleroderma.
    Wigley FM
    Clin Rev Allergy Immunol; 2009 Jun; 36(2-3):150-75. PubMed ID: 19067252
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Angiogenesis Dysregulation in the Pathogenesis of Systemic Sclerosis.
    Cantatore FP; Maruotti N; Corrado A; Ribatti D
    Biomed Res Int; 2017; 2017():5345673. PubMed ID: 28791304
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Adropin inhibits fibrosis in SSc.
    Phillips R
    Nat Rev Rheumatol; 2024 Jun; 20(6):319. PubMed ID: 38702510
    [No Abstract]   [Full Text] [Related]  

  • 60. Targeted therapy for systemic sclerosis: how close are we?
    Ramos-Casals M; Fonollosa-Pla V; Brito-Zerón P; Sisó-Almirall A
    Nat Rev Rheumatol; 2010 May; 6(5):269-78. PubMed ID: 20386562
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.